PAR 0.00% 30.0¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-16

  1. 39 Posts.
    lightbulb Created with Sketch. 18
    Unfortunately about as bleak as we could have thought. 16m cash burn to June 2023 and that's just initiating sites, with sites at capacity as we want, this figure should head consistently north of this and this is just for the Phase 2's in progress.
    We are at the end of July so assuming cash status is now closer to 50m which is approx 3 quarters of runway.
    It would be negligent for a company with this much in progress to have less than two quarters of runway available as contingency at any point in time, so CR is neccessary IMHO before end of September 2023.
    Presumably report on the phase 2 PARA_OA_008 comes out at about this time which is intended to generate a typical PAR bump to then promptly precipitate the impending CR of at least 80m (30% dilution at current cap) to send the price south again....

    MPS VI top line data and possible FDA meeting about potential DMOAD expected in Q4 which will be too late for the CR party so no silver bullet here...

    Any thoughts?

    This is as alwsys based on very limited financial data on projected costs and alternative plans for funding presented by PAR, so assuming shareholders will wear it..







 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
0.000(0.00%)
Mkt cap ! $104.9M
Open High Low Value Volume
30.0¢ 31.0¢ 29.5¢ $89.62K 294.9K

Buyers (Bids)

No. Vol. Price($)
3 20607 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 16773 1
View Market Depth
Last trade - 16.10pm 16/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.